- Home
- SOAR vs EVAX Comparison
SOAR vs EVAX Comparison
Compare SOAR & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOAR
- EVAX
- Stock Information
- Founded
- SOAR 2021
- EVAX 2008
- Country
- SOAR United States
- EVAX Denmark
- Employees
- SOAR N/A
- EVAX N/A
- Industry
- SOAR Blank Checks
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SOAR Finance
- EVAX Health Care
- Exchange
- SOAR Nasdaq
- EVAX Nasdaq
- Market Cap
- SOAR 9.3M
- EVAX 8.7M
- IPO Year
- SOAR N/A
- EVAX 2021
- Fundamental
- Price
- SOAR $0.21
- EVAX $3.09
- Analyst Decision
- SOAR
- EVAX Strong Buy
- Analyst Count
- SOAR 0
- EVAX 2
- Target Price
- SOAR N/A
- EVAX $11.00
- AVG Volume (30 Days)
- SOAR 2.9M
- EVAX 234.6K
- Earning Date
- SOAR 11-18-2024
- EVAX 10-31-2024
- Dividend Yield
- SOAR N/A
- EVAX N/A
- EPS Growth
- SOAR N/A
- EVAX N/A
- EPS
- SOAR N/A
- EVAX N/A
- Revenue
- SOAR $102,271,000.00
- EVAX $3,295,000.00
- Revenue This Year
- SOAR N/A
- EVAX $4,845.21
- Revenue Next Year
- SOAR N/A
- EVAX $30.30
- P/E Ratio
- SOAR N/A
- EVAX N/A
- Revenue Growth
- SOAR 97.25
- EVAX N/A
- 52 Week Low
- SOAR $0.17
- EVAX $3.05
- 52 Week High
- SOAR $4.50
- EVAX $68.05
- Technical
- Relative Strength Index (RSI)
- SOAR 42.74
- EVAX 26.28
- Support Level
- SOAR $0.19
- EVAX $3.17
- Resistance Level
- SOAR $0.29
- EVAX $3.90
- Average True Range (ATR)
- SOAR 0.03
- EVAX 0.58
- MACD
- SOAR -0.00
- EVAX 0.02
- Stochastic Oscillator
- SOAR 21.08
- EVAX 1.31
About SOAR Volato Group Inc.
Volato Group Inc operates an aircraft ownership program, provides ad-hoc charter flights, sells deposit products, and manages aircraft for owners in the private aviation industry. It offers fractional ownership, aircraft management, jet cards, deposit, and charter programs. The company's fractional programs provides flexible hours and a revenue share for owners in a fleet of HondaJets, optimized for missions of up to four passengers.
About EVAX Evaxion Biotech A/S
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.